Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey

• Published in: Psychiatry and clinical psychopharmacology 2019-10, Vol.29 (4), p.722-729
• Main Authors: Cikili Uytun, Merve, Çetin, Fatih Hilmi, Babadağı, Zehra
• Format: Article
• Language: English
• Subjects: ADHD; Concerta; functionality; Medikinet retard; Methylphenidate; social
• ISSN: 2475-0573; 2475-0581
• DOI: 10.1080/24750573.2019.1609153

OBJECTIVE: Medikinet retard® is a nonosmotic, extended-release formulation of Methylphenidate (MPH) and has been used in Turkey for the last 4-5 years. The aim of our study is to compare the efficacy on functionality of Medikinet retard® and Concerta® and their adverse events. METHODS: Participants were referred to the Kayseri Training and Research Hospital and followed up there between August 2016 and June 2018. This study design is a 16-week prospective trial, each child received 16 weeks of OROS-MPH or MPH-ER. A total of 103 children were enrolled in the study, but only 70 children (n =  35 concerta, n = 35 medikinet retard) completed the study. Weiss Functional Impairment Rating Scale-Parent Report Form (WFIRS-P) and Barkley Side Effect Rating Scale (BSERS) were used for assessment. RESULTS: In both treatment groups, children improved significantly over time, both in intensity and in the number of problems. Regarding the social problems, Medikinet retard® was superior to the Concerta in terms of effects. The side effects of insomnia and euphoria were seen more common in the Concerta® group than the Medikinet retard®. Additionally, the mean severity scores of euphoria were shown higher in the Concerta® group than the Medikinet retard. CONCLUSION: From this study, we concluded that Medikinet retard® is also an effective and safety MPH formulation.